Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery

Journal of Neuro-Oncology

Volumn 108, Issue 1, 2012, Pages 89-97

  Stummer, Walter ^a   Meinel, Thomas ^b   Ewelt, Christian ^a   Martus, Peter ^c   Jakobs, Olga ^c   Felsberg, Jörg ^d   Reifenberger, Guido ^d  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Clinstud GmbH   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Glioblastoma; O6 methylguanine DNA methyltransferase; Radiochemotherapy; Resection; Survival; Temozolomide

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ARTICLE; BRAIN SURGERY; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DNA METHYLATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; FOLLOW UP; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; POSTOPERATIVE PERIOD; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROSPECTIVE STUDY; SURVIVAL TIME; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COHORT STUDIES; COMBINED MODALITY THERAPY; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; METHYLATION; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RADIOTHERAPY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84860277233     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0798-3     Document Type: Article

References (31)

1. W Stummer U Pichlmeier T Meinel OD Wiestler F Zanella HJ Reulen 2006 ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial Lancet Oncol 7 392 401 16648043 10.1016/S1470-2045(06)70665-9 1:CAS:528:DC%2BD28XjvFWlsb0%3D
2. MJ McGirt KL Chaichana M Gathinji FJ Attenello K Than A Olivi, et al. 2009 Independent association of extent of resection with survival in patients with malignant brain astrocytoma J Neurosurg 110 156 162 18847342 10.3171/2008.4.17536
3. M Lacroix D Abi-Said DR Fourney ZL Gokaslan W Shi F DeMonte, et al. 2001 A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival J Neurosurg 95 190 198 11780887 10.3171/jns.2001.95.2.0190 1:STN:280:DC%2BD38%2FlsFGitA%3D%3D (Pubitemid 32799739)
4. R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoorn, et al. 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 15758009 10.1056/NEJMoa043330 1:CAS:528: DC%2BD2MXit1Wksbk%3D (Pubitemid 40349501)
5. R Stupp ME Hegi WP Mason MJ van den Bent MJ Taphoorn RC Janzer, et al. 2009 Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 459 466 19269895 10.1016/S1470-2045(09)70025-7 1:CAS:528:DC%2BD1MXlsVKhs74%3D
6. FK Albert M Forsting K Sartor HP Adams S Kunze 1994 Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis Neurosurgery 34 45 60 8121569 10.1227/00006123-199401000-00008 1:STN:280:DyaK2c7ms12ksg%3D%3D
7. W Stummer MA Kamp 2009 The importance of surgical resection in malignant glioma Curr Opin Neurol 22 645 649 19738467 10.1097/WCO.0b013e3283320165
8. ME Hegi AC Diserens T Gorlia MF Hamou N de Tribolet 2005 Weller Met al. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma N Engl J Med 352 997 1003 15758010 10.1056/NEJMoa043331 1:CAS:528:DC%2BD2MXit1Wktro%3D (Pubitemid 40349502)
9. GD Shah S Kesari R Xu TT Batchelor AM O'Neill FH Hochberg, et al. 2006 Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas Neuro Oncol 8 38 46 16443946 10.1215/S1522851705000529 (Pubitemid 43154449)
10. KE Warren N Patronas AA Aikin PS Albert FM Balis 2001 Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors J Natl Cancer Inst 93 1401 1405 11562391 10.1093/jnci/93.18.1401 1:STN:280: DC%2BD3MrhsVOruw%3D%3D (Pubitemid 32936817)
11. E Galanis JC Buckner MJ Maurer R Sykora R Castillo KV Ballman, et al. 2006 Validation of neuroradiologic response assessment in gliomas: Measurement by RECIST, twodimensional, computer-assisted tumor area, and computer-assisted tumor volume methods Neuro Oncol 8 156 165 16533757 10.1215/15228517-2005-005 (Pubitemid 46542660)
12. J Felsberg M Rapp S Loeser R Fimmers W Stummer M Goeppert, et al. 2009 Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients Clin Cancer Res 15 6683 6693 19861461 10.1158/1078-0432. CCR-08-2801 1:CAS:528:DC%2BD1MXhtlCjsrfP
13. DA Schoenfeld JR Richter 1982 Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint Biometrics 38 163 170 7082758 10.2307/2530299 1:STN:280:DyaL383gs12gtg%3D%3D
14. M Koritzinsky R Seigneuric MG Magagnin T van den Beucken P Lambin BG Wouters 2005 The hypoxic proteome is influenced by gene-specific changes in mRNA translation Radiother Oncol 76 177 186 16098621 10.1016/j.radonc.2005.06.036 1:CAS:528:DC%2BD2MXpslChsbs%3D (Pubitemid 41725445)
15. A Lal H Peters 2001 St Croix B, Haroon ZA, Dewhirst MW, Strausberg RL et al. Transcriptional response to hypoxia in human tumors J Natl Cancer Inst 93 1337 1343 11535709 10.1093/jnci/93.17.1337 1:CAS:528:DC%2BD3MXntVKjurw%3D
16. SM Evans KD Judy I Dunphy WT Jenkins WT Hwang PT Nelson, et al. 2004 Hypoxia is important in the biology and aggression of human glial brain tumors Clin Cancer Res 10 8177 8184 15623592 10.1158/1078-0432.CCR-04-1081 1:CAS:528:DC%2BD2cXhtFGjsrjM (Pubitemid 40053376)
17. DR Collingridge JM Piepmeier S Rockwell JP Knisely 1999 Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue Radiother Oncol 53 127 131 10665789 10.1016/S0167-8140(99)00121-8 1:STN:280:DC%2BD3c7islGmtw%3D%3D
18. T Acker KH Plate 2004 Hypoxia and hypoxia inducible factors (HIF) as important regulators of tumor physiology Cancer Treat Res 117 219 248 15015563 10.1007/978-1-4419-8871-3-14 1:CAS:528:DC%2BD2cXptFKiu7s%3D
19. MD McCarter Y Fong 2001 Role for surgical cytoreduction in multimodality treatments for cancer Ann Surg Oncol 8 38 43 11206223 10.1007/s10434-001-0038-0 1:STN:280:DC%2BD3M7lsFelug%3D%3D (Pubitemid 32126824)
20. KR Hess 1999 Extent of resection as a prognostic variable in the treatment of gliomas J Neurooncol 42 227 231 10433106 10.1023/A:1006118018770 1:STN:280:DyaK1MzmtVCrug%3D%3D (Pubitemid 29322199)
21. WJ Curran Jr CB Scott J Horton JS Nelson AS Weinstein DF Nelson, et al. 1992 Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials J Neurooncol 12 219 227 1583555 10.1007/BF00172709
22. JR Simpson J Horton C Scott WJ Curran P Rubin J Fischbach, et al. 1993 Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials Int J Radiat Oncol Biol Phys 26 239 244 8387988 10.1016/0360-3016(93)90203-8 1:STN:280:DyaK3s3lvFyqsQ%3D%3D (Pubitemid 23156970)
23. B Jeremic B Milicic D Grujicic A Dagovic J Aleksandrovic N Nikolic 2004 Clinical prognostic factors in patients with malignant glioma treated with combined modality approach Am J Clin Oncol 27 195 204 15057161 10.1097/01.coc.0000055059.97106.15 (Pubitemid 38451483)
24. I Ciric NA Vick MA Mikhael J Cozzens T Eller A Walsh 1990 Aggressive surgery for malignant supratentorial gliomas Clin Neurosurg 36 375 383 2295210 1:STN:280:DyaK3c7gslahtA%3D%3D
25. BC Devaux JR O'Fallon PJ Kelly 1993 Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome J Neurosurg 78 767 775 8468607 10.3171/jns.1993.78.5.0767 1:STN:280:DyaK3s3isV2ktw%3D%3D (Pubitemid 23121919)
26. MJ Winger DR Macdonald JG Cairncross 1989 Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma J Neurosurg 71 487 493 2552044 10.3171/jns.1989.71.4.0487 1:STN:280:DyaK3c%2FhtFaqsg%3D%3D (Pubitemid 19244261)
27. ER Laws IF Parney W Huang F Anderson AM Morris A Asher, et al. 2003 Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project J Neurosurg 99 467 473 12959431 10.3171/jns.2003.99.3.0467 (Pubitemid 37040405)
28. GE Keles B Anderson MS Berger 1999 The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere Surg Neurol 52 371 379 10555843 10.1016/S0090- 3019(99)00103-2 1:STN:280:DC%2BD3c%2Fit1Oluw%3D%3D (Pubitemid 29505267)
29. W Stummer HJ Reulen T Meinel U Pichlmeier W Schumacher JC Tonn, et al. 2008 ALA- Glioma Study Group. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias Neurosurgery 62 564 576 18425006 10.1227/01.neu.0000317304.31579.17
30. D Brandsma L Stalpers W Taal P Sminia MJ van den Bent 2008 Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas Lancet Oncol 9 453 461 18452856 10.1016/S1470-2045(08)70125-6 (Pubitemid 351597795)
31. A Lai A Tran PL Nghiemphu WB Pope OE Solis M Selch, et al. 2010 Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme JCO 29 142 148 10.1200/JCO.2010.30.2729